Less is more: low expression of MT1-MMP is optimal to promote migration and tumourigenesis of breast cancer cells

[1]  J. Brugarolas,et al.  Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma , 2016, Molecular and Cellular Biology.

[2]  Yohan Kim,et al.  Quantification of cancer cell extravasation in vivo , 2016, Nature Protocols.

[3]  A. Vincent-Salomon,et al.  p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer , 2016, Oncogene.

[4]  A. Vincent-Salomon,et al.  ARF6–JIP3/4 regulate endosomal tubules for MT1-MMP exocytosis in cancer invasion , 2015, The Journal of cell biology.

[5]  C. Valacca,et al.  TIMP-2 Interaction with MT1-MMP Activates the AKT Pathway and Protects Tumor Cells from Apoptosis , 2015, PloS one.

[6]  Piotr Cieplak,et al.  High-Throughput Multiplexed Peptide-Centric Profiling Illustrates Both Substrate Cleavage Redundancy and Specificity in the MMP Family. , 2015, Chemistry & biology.

[7]  T. Bugge,et al.  The source of matrix-degrading enzymes in human cancer: Problems of research reproducibility and possible solutions , 2015, The Journal of cell biology.

[8]  David J. Barry,et al.  Open source software for quantification of cell migration, protrusions, and fluorescence intensities , 2015, The Journal of cell biology.

[9]  Andreas Plückthun,et al.  Reproducibility: Standardize antibodies used in research , 2015, Nature.

[10]  C. Valacca,et al.  Membrane‐Type 1 Matrix Metalloproteinase Downregulates Fibroblast Growth Factor‐2 Binding to the Cell Surface and Intracellular Signaling , 2015, Journal of cellular physiology.

[11]  R. Ling,et al.  The overexpression membrane type 1 matrix metalloproteinase is associated with the progression and prognosis in breast cancer. , 2015, American journal of translational research.

[12]  Jian Cao,et al.  Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas , 2015, Genes & diseases.

[13]  D. Ribatti.  The chick embryo chorioallantoic membrane as a model for tumor biology. , 2014, Experimental cell research.

[14]  Amy E. Robertson,et al.  Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis. , 2014, Cell reports.

[15]  D. Cvetković,et al.  Quantification of breast cancer cell invasiveness using a three-dimensional (3D) model. , 2014, Journal of visualized experiments : JoVE.

[16]  Dimitris Georgiadis,et al.  A new transcriptional role for matrix metalloproteinase-12 in antiviral immunity , 2014, Nature Medicine.

[17]  Elliott J. Hagedorn,et al.  Traversing the basement membrane in vivo: A diversity of strategies , 2014, The Journal of cell biology.

[18]  F. Nielsen,et al.  ADAM12 redistributes and activates MMP-14, resulting in gelatin degradation, reduced apoptosis and increased tumor growth , 2013, Journal of Cell Science.

[19]  S. Weed,et al.  Quantitative measurement of invadopodia-mediated extracellular matrix proteolysis in single and multicellular contexts. , 2012, Journal of visualized experiments : JoVE.

[20]  L. Walsh,et al.  Analysis of the MMP-dependent and independent functions of tissue inhibitor of metalloproteinase-2 on the invasiveness of breast cancer cells , 2012, Journal of Cell Communication and Signaling.

[21]  M. Zafarullah,et al.  Enhanced Expression of Tissue Inhibitor of Metalloproteinases-4 Gene in Human Osteoarthritic Synovial Membranes and Its Differential Regulation by Cytokines in Chondrocytes , 2011, The open rheumatology journal.

[22]  M. Coppolino,et al.  Phosphorylation of Membrane Type 1-Matrix Metalloproteinase (MT1-MMP) and Its Vesicle-associated Membrane Protein 7 (VAMP7)-dependent Trafficking Facilitate Cell Invasion and Migration* , 2011, The Journal of Biological Chemistry.

[23]  A. Dufour,et al.  Inhibition of Matrix Metalloproteinase 14 (MMP-14)-mediated Cancer Cell Migration* , 2011, The Journal of Biological Chemistry.

[24]  R. Jain,et al.  Cancer cell-associated MT1-MMP promotes blood vessel invasion and distant metastasis in triple-negative mammary tumors. , 2011, Cancer research.

[25]  M. Seiki,et al.  Targeting the Warburg Effect That Arises in Tumor Cells Expressing Membrane Type-1 Matrix Metalloproteinase* , 2011, The Journal of Biological Chemistry.

[26]  M. Seiki,et al.  A Membrane Protease Regulates Energy Production in Macrophages by Activating Hypoxia-inducible Factor-1 via a Non-proteolytic Mechanism* , 2010, The Journal of Biological Chemistry.

[27]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. , 2010, Seminars in cancer biology.

[28]  A. Chambers,et al.  Human 21T breast epithelial cell lines mimic breast cancer progression in vivo and in vitro and show stage-specific gene expression patterns , 2010, Laboratory Investigation.

[29]  M. Bissell,et al.  Apical polarity in three-dimensional culture systems: where to now? , 2010, Journal of biology.

[30]  A. Strongin,et al.  Timp‐2 binding with cellular MT1‐MMP stimulates invasion‐promoting MEK/ERK signaling in cancer cells , 2009, International journal of cancer.

[31]  J. Dietl,et al.  Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature , 2009, BMC Cancer.

[32]  A. Strongin,et al.  Epigenetic Control of the Invasion-promoting MT1-MMP/MMP-2/TIMP-2 Axis in Cancer Cells* , 2009, Journal of Biological Chemistry.

[33]  Ajit Varki,et al.  Molecular basis of metastasis. , 2009, The New England journal of medicine.

[34]  M. Sogayar,et al.  Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential , 2009, BMC Cancer.

[35]  S. Weiss,et al.  Breaching the basement membrane: who, when and how? , 2008, Trends in cell biology.

[36]  Mina J Bissell,et al.  Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. , 2008, Seminars in cancer biology.

[37]  S. Yamada,et al.  MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease , 2008, Oncogene.

[38]  Roy A Jensen,et al.  A human breast cell model of preinvasive to invasive transition. , 2008, Cancer research.

[39]  W. Stetler-Stevenson.  The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2 , 2008, Cancer and Metastasis Reviews.

[40]  A. Strongin,et al.  Tissue Inhibitor of Metalloproteinases-2 Binding to Membrane-type 1 Matrix Metalloproteinase Induces MAPK Activation and Cell Growth by a Non-proteolytic Mechanism* , 2008, Journal of Biological Chemistry.

[41]  M. Takigawa,et al.  Novel Transcription Factor-Like Function of Human Matrix Metalloproteinase 3 Regulating the CTGF/CCN2 Gene , 2008, Molecular and Cellular Biology.

[42]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[43]  G. Christofori.  New signals from the invasive front , 2006, Nature.

[44]  Françoise Seillier-Moiseiwitsch,et al.  Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. , 2006, Cancer research.

[45]  Mina J Bissell,et al.  Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation. , 2005, Seminars in cancer biology.

[46]  A. Noël,et al.  Membrane type-matrix metalloproteinases and tumor progression. , 2005, Biochimie.

[47]  W. Stetler-Stevenson,et al.  TIMP-2: an endogenous inhibitor of angiogenesis. , 2005, Trends in molecular medicine.

[48]  M. Sung,et al.  Matrix metalloproteinase‐2 (MMP‐2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP‐ribose) polymerase (PARP) in vitro , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[49]  M. Bernardo,et al.  Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes. , 2003, Biochemical and biophysical research communications.

[50]  D. Edwards,et al.  Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP). , 2003, The Biochemical journal.

[51]  Maria Pavlaki,et al.  Matrix metalloproteinase inhibitors (MMPIs): The beginning of phase I or the termination of phase III clinical trials , 2003, Cancer and Metastasis Reviews.

[52]  Motoharu Seiki,et al.  Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. , 2003, Cancer letters.

[53]  R. Visse,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[54]  J. Foidart,et al.  Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. , 2003, Matrix biology : journal of the International Society for Matrix Biology.

[55]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[56]  H. Mori,et al.  CD44 directs membrane‐type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin‐like domain , 2002, The EMBO journal.

[57]  J. Scholefield,et al.  Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial , 2002, British Journal of Cancer.

[58]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[59]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[60]  D. Gingras,et al.  Activation of the extracellular signal‐regulated protein kinase (ERK) cascade by membrane‐type‐1 matrix metalloproteinase (MT1‐MMP) , 2001, FEBS letters.

[61]  Hiroshi Sato,et al.  Homophilic complex formation of MT1‐MMP facilitates proMMP‐2 activation on the cell surface and promotes tumor cell invasion , 2001, The EMBO journal.

[62]  A. Strongin,et al.  Mutation Analysis of Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) , 2001, The Journal of Biological Chemistry.

[63]  J. Foidart,et al.  Type IV collagen induces matrix metalloproteinase 2 activation in HT1080 fibrosarcoma cells. , 2000, Experimental cell research.

[64]  M. Duffy,et al.  Metalloproteinases: role in breast carcinogenesis, invasion and metastasis , 2000, Breast Cancer Research.

[65]  A. Noël,et al.  High levels of TIMP‐2 correlate with adverse prognosis in breast cancer , 2000, International journal of cancer.

[66]  P. Wingfield,et al.  Biophysical and Functional Characterization of Full-length, Recombinant Human Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) Produced in Escherichia coli , 1999, The Journal of Biological Chemistry.

[67]  B. Davidson,et al.  MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma--a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. , 1999, Gynecologic oncology.

[68]  L. Matrisian,et al.  Changing views of the role of matrix metalloproteinases in metastasis. , 1997, Journal of the National Cancer Institute.

[69]  J. Nesland,et al.  High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[70]  J. Mohler,et al.  In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer , 1997, Clinical & Experimental Metastasis.

[71]  F. Sarkar,et al.  Enhanced expression of tissue inhibitor of metalloproteinase‐2 (TIMP‐2) in the stroma of breast carcinomas correlates with tumor recurrence , 1994, International journal of cancer.

[72]  L. Liotta,et al.  Tumor cell invasion inhibited by TIMP-2. , 1991, Journal of the National Cancer Institute.

[73]  J. Connolly,et al.  Tumor progression in four mammary epithelial cell lines derived from the same patient. , 1990, Cancer research.

[74]  Y. DeClerck,et al.  Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. , 1990, Journal of the National Cancer Institute.

[75]  J. Marshall.  Transwell(®) invasion assays. , 2011, Methods in molecular biology.

[76]  A. Strongin.  Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy. , 2010, Biochimica et biophysica acta.

[77]  Hongxia Li,et al.  Zymography and reverse zymography for detecting MMPs and TIMPs. , 2010, Methods in molecular biology.

[78]  H. Ishii,et al.  Overexpression of MT1-MMP is insufficient to increase experimental liver metastasis of human colon cancer cells. , 2008, International journal of molecular medicine.

[79]  J. Nesland,et al.  High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma , 2004, Clinical & Experimental Metastasis.